Scope of RNA Vaccine Federal Funding Delineated in New Analysis

An analysis of federal funding for RNA vaccine research shows the potential of the technology both for preventing infectious diseases and for treating other conditions from cancer to Alzheimer’s.

Researchers identified 178 active grants in RNA vaccine research from the NIH that started between 1997 and 2025, totaling $1.65 billion in funding. The top three areas of study are “viruses, RNA technology, and cancer.” The most frequently funded areas of research were “COVID-19 (29 grants) and, close behind, HIV (24 grants). Among cancers, the most grants went to the study of solid tumors (eight grants) and melanoma (three grants).” Other potential applications, ranging from “tick-borne illnesses and parasitic infections to eye disease and syphilis,” were included as well.

The federal grant money has “already produced more than 2,300 scientific papers that have been cited by scientists more than 149,000 times,” covering everything from “basic lab research to promising advances in patient care.”

The scientists behind the study urged “careful consideration of the benefits the technology could have for patients and the economy.”